<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852017000300183</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultados histopatológicos de segunda revisión por carcinoma urotelial vesical no invasor al músculo: ¿realmente es útil?]]></article-title>
<article-title xml:lang="en"><![CDATA[Second-look histopathologic results in non-muscle-invasive urothelial carcinoma of the bladder: Is repeat resection necessary?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chamlati-Cuello]]></surname>
<given-names><![CDATA[JM.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garza-Gangemi]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gonzaga-Carlos]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iturriaga-Goyon]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillejos-Molina]]></surname>
<given-names><![CDATA[RA.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Departamento de Urología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>77</volume>
<numero>3</numero>
<fpage>183</fpage>
<lpage>190</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852017000300183&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852017000300183&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852017000300183&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  en resecciones repetidas en cáncer de vejiga existe una alta tasa de tumor residual. En la actualidad, la verdadera utilidad y el efecto de este tratamiento son inciertos.  OBJETIVO:  describir los resultados de la segunda revisión en pacientes con cáncer de vejiga no invasor al músculo, según la tasa de re-estadificación y coexistencia de tumor residual.  MATERIALES Y MÉTODOS:  estudio retrospectivo y observacional, efectuado en pacientes con resección transuretral de vejiga por carcinoma urotelial vesical no invasor al músculo, de 1984 a 2017, en el Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Se analizó la tasa de tumor residual y re-estadificación en la segunda revisión.  RESULTADOS: de 556 expedientes, se incluyeron para el análisis final 117 casos, de los que solo 43 (37.7%) formaron parte del grupo de pacientes con segunda revisión. El diámetro del tumor primario fue mayor en el grupo de estudio (3 ± 2 vs 2.3 ± 1.5 cm, p=0.03), al igual que el tumor residual en 17 (39.5%) casos y 1 (2.3%) expresó tumor con invasión al músculo. En los pacientes con tumor residual, 2 (11.7%) tuvieron un incremento en estadio y 3 (17.64%) un cambio de grado bajo a grado alto.  CONCLUSIONES:  existe un alto porcentaje de tumor residual en pacientes con diagnóstico de cáncer de vejiga no invasor al músculo, inicialmente tratados con resección transuretral de vejiga, además de una tasa re-estadificación considerable.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  There is a high rate of residual tumor reported in repeat resections performed in cases of bladder cancer. The real usefulness and effect of this practice are currently in doubt.  OBJECTIVE:  To describe the results of a second-look resection in patients with non-muscle invasive bladder cancer in relation to the rates of re-staging and residual tumor.  MATERIALS AND METHODS:  A retrospective, observational study was conducted on patients that underwent transurethral resection of the bladder due to non-muscle-invasive urothelial carcinoma of the bladder at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, within the time frame of 1984 to 2017. Second-look residual tumor and re-staging rates were analyzed.  RESULTS:  Out of 556 medical records, the final analysis included 117 cases, of which only 43 patients (37.75%) underwent a second-look resection. Primary tumor diameter was larger in the study group (3 ± 2 vs 2.3 ± 1.5 cm, p=0.03). Residual tumor was found in 17 cases (39.5%), one of which (2.3%) presented with muscle-invasive disease. In the patients with residual tumor, there was an increase in stage in 2 cases (11.76%), and 3 cases (17.64%) had a change from low grade to high grade tumor.  CONCLUSIONS:  There is a high percentage of residual tumor in patients diagnosed with non-muscle-invasive urothelial carcinoma of the bladder that underwent initial transurethral resection of the bladder, as well as a considerable re-staging rate.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[cáncer de vejiga]]></kwd>
<kwd lng="es"><![CDATA[segunda revisión]]></kwd>
<kwd lng="es"><![CDATA[tumor residual]]></kwd>
<kwd lng="es"><![CDATA[re-estadificación]]></kwd>
<kwd lng="en"><![CDATA[Bladder cancer]]></kwd>
<kwd lng="en"><![CDATA[Second-look resection]]></kwd>
<kwd lng="en"><![CDATA[Residual tumor]]></kwd>
<kwd lng="en"><![CDATA[Re-staging]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ervik]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Estimated cancer incidence, mortality and prevalence worldwide in 2012]]></source>
<year>2012</year>
<publisher-name><![CDATA[GLOBOCAN]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Catto]]></surname>
<given-names><![CDATA[JWF]]></given-names>
</name>
<name>
<surname><![CDATA[Dalbagni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and Risk Factors of Urothelial Bladder Cancer]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2013</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>234-41</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaya]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Palou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cosentino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A second transurethral resection could be not necessary in all high grade non-muscle-invasive bladder tumors]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2013</year>
<volume>36</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>539-44</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jakse]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Algaba]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Malmström]]></surname>
<given-names><![CDATA[PU]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Second-Look TUR in T1 Transitional Cell Carcinoma: Why?]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2004</year>
<volume>45</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>539-46</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[T1G3 BladderTumours : The Case for Conservative Treatment]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2004</year>
<volume>45</volume>
<page-range>401-5</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baltaci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bozlu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yildirim]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2015</year>
<volume>116</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>721-6</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Babjuk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Böhle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[EAU Guidelines on Bladder Cancer]]></source>
<year>2016</year>
<page-range>1-45</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Divrik]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Ahin]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Yildirim]]></surname>
<given-names><![CDATA[Ü]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2010</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>185-90</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Palou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[García-tello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving Bacillus Calmette-Guérin]]></article-title>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2014</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>164-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van der Heijden]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Witjes]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recurrence, Progression, and Follow-Up in Non-Muscle-Invasive Bladder Cancer]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2009</year>
<volume>8</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>556-62</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Urdaneta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Solsona]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Palou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravesical Chemotherapy and BCG for the Treatment of Bladder Cancer : Evidence and Opinion]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2008</year>
<volume>7</volume>
<page-range>542-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Donat]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality control in transurethral resection of bladder tumours]]></article-title>
<source><![CDATA[BJUI]]></source>
<year>2008</year>
<page-range>1242-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fritsche]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Burger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Svatek]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort]]></article-title>
<source><![CDATA[Eur Urol]]></source>
<year>2010</year>
<volume>57</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>300-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Barky]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Sebaey]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Eltabey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The importance of second-look transurethral resection for superficial bladder cancer]]></article-title>
<source><![CDATA[J Clin Urol]]></source>
<year>2015</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shim]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Noh Il]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical significance of a second transurethral resection for T1 high-grade bladder cancer : Results of a prospective study]]></article-title>
<source><![CDATA[Korean J Urol]]></source>
<year>2015</year>
<page-range>429-34</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Herr]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of re-resection in non-muscle-invasive bladder cancer]]></article-title>
<source><![CDATA[Sci World J]]></source>
<year>2011</year>
<page-range>283-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hashine]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ide]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nakashima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Results of second transurethral resection for high-grade T1 bladder cancer]]></article-title>
<source><![CDATA[Urol Ann]]></source>
<year>2016</year>
<page-range>10-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giunchi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Panzacchi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Capizzi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of inter-observer variability and quantification of muscularis propria in the pathological staging of bladder cancer]]></article-title>
<source><![CDATA[Clin Genitourin Cancer]]></source>
<year>2016</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>307-12</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tosoni]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Sauter]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2000</year>
<volume>85</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48-53</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Ismail]]></surname>
<given-names><![CDATA[IY]]></given-names>
</name>
<name>
<surname><![CDATA[Eltobgy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer]]></article-title>
<source><![CDATA[J Endourol]]></source>
<year>2010</year>
<volume>24</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2047-50</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Husillos-Alonso]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez- Fernández]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Amo]]></surname>
<given-names><![CDATA[Heranz]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MINERVA]]></article-title>
<source><![CDATA[Urol Nefrol]]></source>
<year>2014</year>
<volume>66</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>233-40</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Divrik]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Yildirim]]></surname>
<given-names><![CDATA[Ü]]></given-names>
</name>
<name>
<surname><![CDATA[Zorlu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The effect of repeat transurethral resection on recurrence and progression rates in patients with t1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2006</year>
<volume>175</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1641-4</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
